Comparison of molecular abnormalities in vulvar and vaginal melanomas

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

(2013) Paolo A Ascierto et al.   LANCET ONCOLOGY

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

(2012) A. M. Menzies et al.   CLINICAL CANCER RESEARCH

Clinicopathologic study of 85 cases of melanoma of the female genitalia

(2012) Win J. Tcheung et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET

KIT Pathway Alterations in Mucosal Melanomas of the Vulva and Other Sites

(2011) K. Omholt et al.   CLINICAL CANCER RESEARCH

Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy

(2011) Arne Warth et al.   EUROPEAN RESPIRATORY JOURNAL

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification

(2011) Jun Guo et al.   JOURNAL OF CLINICAL ONCOLOGY

Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites

(2009) Shigeki Sekine et al.   VIRCHOWS ARCHIV

Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas

(2008) I Satzger et al.   BRITISH JOURNAL OF CANCER